Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 1,250 shares of the company’s stock on the open market in a transaction dated Thursday, August 28th. The stock was sold at an average price of $19.74, for a total transaction of $24,675.00. Following the transaction, the senior vice president now directly owns 30,933 shares in the company, valued at approximately $610,617. The sale was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on AMRI. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Albany Molecular Research (NASDAQ:AMRI) opened at 19.33 on Thursday. Albany Molecular Research has a 1-year low of $9.71 and a 1-year high of $22.30. The stock has a 50-day moving average of $19.68 and a 200-day moving average of $17.90. The company has a market cap of $610.0 million and a P/E ratio of 38.78.

Albany Molecular Research (NASDAQ:AMRI) last announced its earnings results on Tuesday, August 5th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Receive News & Ratings for Albany Molecular Research Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.